上海交通大学学报（医学版）

上海交通大学学报（医学版）

• 述评 • 上一篇    下一篇

肺癌治疗靶向基因研究进展及临床分子病理检测

张 杰   

  1. 上海交通大学附属胸科医院病理科， 上海 200030
  • 出版日期:2013-10-28 发布日期:2013-10-31
  • 作者简介:张 杰（1957—）, 男， 主任医师， 硕士生导师; 电子信箱: jiezhang49@hotmail.com。

Research progress of genes in lung cancer target therapy and clinical molecular pathological detection

ZHANG Jie   

  1. Department of Pathology, Shanghai Chest Hospital, Shanghai Jiaotong University, Shanghai 200030, China
  • Online:2013-10-28 Published:2013-10-31

PDF (PC)

2010

摘要：

以表皮生长因子受体(EGFR)、间变淋巴瘤激酶（ALK）基因融合变异等为治疗靶标的肺癌分子靶向治疗取得了长足进步。文章介绍了与EGFR酪氨酸激酶抑制剂（EGFR-TKI）和ALK基因融合变异抑制剂克唑替尼（Crizotinib）治疗用药相关的EGFR、K-RAS、BRAF、C-MET、EML4-ALK、ROS1等肺癌治疗靶向基因的作用原理，并详细阐述了上述基因分子病理检测的注意事项，包括对检测标本的要求、检测方法的选择和基因检测质量控制的要求。

关键词: 肺癌, 靶向治疗, 表皮生长因子受体, 间变淋巴瘤激酶, 分子病理

Abstract:

Considerable progress has been made in lung cancer therapy targeted on epidermal growth factor receptor (EGFR) mutation and anaplastic lymphoma kinase (ALK) infusion. The mechanism of genes in lung cancer target therapy, such as EGFR, K-RAS, BRAF, C-MET, EML4-ALK, ROS1 and their relationship with EGFR tyrosine kinase inhibitor (EGFR-TKI) and ALK gene infusion inhibitor are introduced. Meanwhile, important requirements in gene detection are elaborated, including the requirements for specimens, choice of methods and quality control in gene detection of lung cancer.

Key words: lung cancer, target therapy, epidermal growth factor receptor, anaplastic lymphoma kinase, molecular pathology